AI Terminal
Kamada Ltd.
Foreign Filer Report • Mar 15, 2022
6874_rns_2022-03-15_a3029332-22a7-4cce-b98b-cfbfae797be0.pdf
Foreign Filer Report
Open in ViewerOpens in native device viewer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the Month of March 2022
Commission File Number 001-35948
Kamada Ltd. (Translation of registrant's name into English)
2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____
This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891 and 333-233267.
The following exhibit is attached:
99.1 Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 15, 2022 KAMADA LTD.
By: /s/ Yifat Philip
Yifat Philip Vice President General Counsel and Corporate Secretary
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
| 99.1 | Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant | ||||
|---|---|---|---|---|---|
| Growth Expected in 2022 |
Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
- Total Revenues for Fiscal Year 2021 were \$103.6 Million and Fourth Quarter 2021 Revenues were \$31.5 Million.
- Fiscal Year 2022 Revenues are Expected to Range Between \$125 Million to \$135 Million, Representing a 20% to 30% Increase over 2021; 2022 EBITDA Margins Anticipated Between 12%-15%, Representing More Than 2.5X over 2021 EBITDA.
- Integration of Newly Acquired Portfolio of Four FDA-Approved Commercial Products is Progressing as Planned with Expanded Sales in International Markets.
- Advancing the Plan for the Opening of New U.S. Plasma Collection Centers.
- Company Expands U.S. Leadership Team with Multiple Key Hires to Drive Sales of Proprietary Products and Expansion of Plasma Collection Operations.
- Added Two New Biosimilar Product Candidates in Israel; Increasing the Expected Potential Collective Annual Peak Sales of the Entire Biosimilar Portfolio of 11 Product Candidates to over \$40 Million.
- Pivotal Phase 3 InnovAATe Trial for Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Progressing with the Opening of New Sites to Expand Recruitment.
- GLASSIA® Royalty Payments from Takeda to Commence During Q2 2022.
REHOVOT, Israel – March 15, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the 12 and three months ended December 31, 2021.
"2021 was a transformational year for Kamada in our path toward becoming a global leader in the plasma-derived specialty hyperimmune market. With the recent acquisition of the portfolio of four FDA-approved commercial products, that generated annual global revenue in 2021 of approximately \$41.9 million with over 50% gross margins of which approximately \$5.4 million of revenue was recognized by the Company, and the establishment of Kamada Plasma, our U.S. based plasma collection company, we are embarking on a new and exciting chapter in the company's evolution. We are building on the strong foundation established over the years and entering 2022 as a "New Kamada" – a fully integrated specialty plasma company, with six FDAapproved products and strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries," said Amir London, Kamada's Chief Executive Officer.
"Our business performed as expected during 2021, and we look ahead to 2022 for which our revenue guidance is between \$125 million to \$135 million, representing a 20% to 30% growth compared to 2021, with expected EBITDA margins of 12% to 15%, which would represent more than 2.5x of the 2021 EBITDA. This strong guidance reflects the benefits stemmed from our new undertaken strategic direction and our expectation of rapid return to revenue and profitability growth in 2022. We further expect continued growth at a double-digit rate in the foreseeable years ahead."
"I am happy to report that over the past few months we have made significant progress with all our key growth catalysts, and we are implementing the needed steps to realize our significant growth potential. The integration of the newly acquired immunoglobulins portfolio is well underway in the U.S., as well as in the international markets. We are progressing with our plans for the opening of new plasma collection centers in the U.S. We have expanded our portfolio of Biosimilar product candidates to be distributed in the Israeli market, increasing our expected peak potential annual biosimilar sales, within several years of launch, to over \$40 million. In addition, we are expanding our inhaled AAT pivotal Phase 3 trial with up to six additional clinical sites to be opened by mid-2022. Further, commencing in the second quarter of 2022, we are expecting to begin receiving GLASSIA royalty payments from Takeda, improving our profitability and cash position," concluded Mr. London.
Fiscal Year 2022 Guidance
Kamada currently expects to generate fiscal year 2022 total revenues in a range of \$125 million to \$135 million which would represent a 20% to 30% growth compared to fiscal year 2021. The Company also anticipates generating EBITDA, during 2022, at a rate of 12% to 15% of total revenues, representing more than 2.5x of the EBITDA for the year ended December 31, 2021.
Financial Highlights for the Year Ended December 31, 2021
- Total revenues were \$103.6 million in the year ended December 31, 2021, as compared to \$133.2 million recorded in the year ended December 31, 2020. This decrease was primarily due to the transition of GLASSIA manufacturing to Takeda resulting in an overall \$38.7 million year over year decrease, and a year over year decrease of \$6.4 million in KEDRAB sales to Kedrion as a result of a high level of product inventory at Kedrion as of December 31, 2020, due to the COVID-19 pandemic effect on KEDRAB sales by Kedrion during 2020. These decreases were partially offset by \$5.4 million of revenues generated from the newly acquired portfolio between November 22, 2021, through December 31, 2021, as well as an increase in revenues of our other Proprietary products.
- Gross profit was \$30.3 million in the year ended December 31, 2021, compared to \$47.6 million reported in the year ended December 31, 2020. The decrease compared to 2020 is primarily attributed to the overall change in product sales mix, specifically the decrease in sales of GLASSIA to Takeda and KEDRAB to Kedrion (as detailed above).
- Net loss was \$2.2 million, or \$(0.05) per share, in the year ended December 31, 2021, as compared to net income of \$17.1 million, or \$0.38 per share, in the year ended December 31, 2020.
- EBITDA, as detailed in the tables below, was \$5.4 million in the year ended December 31, 2021, as compared to \$25.1 million in the year ended December 31, 2020. Adjusted EBITDA, excluding certain costs, as detailed in the tables below, was \$7.2 million for the year ended December 31, 2021.
- Non-IFRS adjusted EBITDA for the year ended December 31, 2021, as detailed in the reconciliation table below, is presented excluding the following: (i) approximately \$1.2 million in legal and other related fees associated with completing the acquisition transactions; and (ii) an expense of approximately \$0.6 million related to excess severance remuneration for the employees who were laid-off as part of downsizing, following the transition of GLASSIA manufacturing to Takeda.
- Cash used in operating activities was \$8.8 million in the year ended December 31, of 2021, as compared to cash provided by operating activities of \$19.1 million in the year ended December 31, 2020.
Financial Highlights for the Three Months Ended December 31, 2021
- Total revenues were \$31.5 million in the fourth quarter of 2021, equivalent to the revenues recorded in the fourth quarter of 2020.
- Gross profit was \$6.6 million in the fourth quarter of 2021, compared to \$10.2 million reported in the fourth quarter of 2020.
- Net loss was \$5.0 million, or \$(0.11) per share, in the fourth quarter of 2021, as compared to net income of \$1.6 million, or \$0.04 per share, in the fourth quarter of 2020.
- EBITDA, as detailed in the tables below, was \$(1.3) million in the fourth quarter of 2021, as compared to \$4.0 million in the fourth quarter of 2020. Adjusted EBITDA, excluding certain costs, as detailed in the table below, was \$(0.5) million in the fourth quarter of 2021.
- Non-IFRS adjusted EBITDA for the fourth quarter of 2021, as detailed in the reconciliation table below, is presented excluding approximately \$0.7 million in legal and other related fees associated with completing the acquisitions transaction.
- Cash used in operating activities was \$5.0 million in the fourth quarter of 2021, as compared to cash provided by operating activities of \$12.7 million in the fourth quarter of 2020.
Balance Sheet Highlights
As of December 31, 2021, the Company had cash, cash equivalents, and short-term investments of \$18.6 million, as compared to \$109.3 million on December 31, 2020. The primary use of cash during 2021 was the acquisition of four FDA-approved plasma-derived hyperimmune commercial products. Kamada's working capital as of December 31, 2021, comprising of current assets (excluding cash and cash equivalents, and short-term investments) net of current liabilities, totaled \$57.4 million, representing an increase of \$13.7 million compared to December 31, 2020.
The Company secured a \$40 million credit facility from Bank Hapoalim, Israel's leading commercial bank. The credit facility is comprised of a \$20 million 5-year term loan and a \$20 million short-term revolving credit facility. As of December 31, 2021, the Company drew-down the entire long-term loan and did not utilize the short-term revolving credit facility.
Conference Call
Kamada management will host an investment community conference call on Tuesday, March 15, 2022, at 8:30am Eastern Time to present the Company's results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13727620. The call will also be webcast live on the Internet at:
https://viavid.webcasts.com/starthere.jsp?ei=1533883&tp_key=876a5d54ec
Non-IFRS financial measures
We present EBITDA and adjusted EBITDA because we use this non-IFRS financial measure to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes this non-IFRS financial measure are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company's core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA and adjusted EBITDA are defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, plus non-cash share-based compensation expenses and certain other costs.
About Kamada
Kamada Ltd. (the "Company") is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasmaderived biopharmaceutical market. The Company's commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) 2022 revenue guidance in the range of \$125 million to \$135 million, a 20% to 30% growth compared to 2021, 2) 2022 EBITDA, as a rate of total revenues, of 12% to 15%, 3) expected continued growth at a double-digit rate in the foreseeable years ahead, 4) expectation of rapid return to revenue and profitability growth in 2022, 5) plans for the opening of new plasma collection centers in the U.S., 6) expectation of peak potential annual biosimilar sales to over \$40 million for the 11 Biosimilar product candidates to be distributed in the Israel market, 7) expansion of inhaled AAT pivotal Phase 3 trial with up to six additional clinical sites to be opened by mid-2022, 8) receipt of GLASSIA royalty payments from Takeda during the second quarter of 2022, 9) optimism about strategic business development opportunities that will utilize and expand our core plasma-derived development, manufacturing, and commercialization expertise, and 10) the belief that those opportunities are may be significant steps toward accomplishing our strategic goal of becoming a fully integrated specialty plasma company. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, availability of sufficient raw materials required to maintain manufacturing plans, disruption to the supply chain due to COVID-19 pandemic, continuation of inbound and outbound international delivery routes, impact of the workforce downsizing plan, continued demand for Kamada's products, including GLASSIA and KEDRAB and its Distribution segment related products in Israel, financial conditions of the Company's customer, suppliers and services providers, Kamada's ability to integrate the new product portfolio into its current product portfolio, Kamada's ability to grow the revenues of this new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the recent acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada's ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada's filings with the U.S. Securities and Exchange Commission (the "SEC") including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC's website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACTS:
Chaime Orlev Chief Financial Officer [email protected]
Bob Yedid LifeSci Advisors, LLC 646-597-6989 [email protected]
CONSOLIDATED STATEMENTS OF FINANCIAL POSITTION
| As of December 31, | ||||
|---|---|---|---|---|
| 2021 | 2020 | |||
| U.S. Dollars in thousands | ||||
| Assets | ||||
| Current Assets | ||||
| Cash and cash equivalents | \$ 18,587 \$ |
70,197 | ||
| Short-term investments | - | 39,069 | ||
| Trade receivables, net | 35,162 | 22,108 | ||
| Other accounts receivables | 8,872 | 4,524 | ||
| Inventories | 67,423 | 42,016 | ||
| Total Current Assets | 130,044 | 177,914 | ||
| Non-Current Assets | ||||
| Property, plant and equipment, net | 26,307 | 25,679 | ||
| Right-of-use assets | 3,092 | 3,440 | ||
| Intangible assets, Goodwill and other long-term assets | 153,663 | 1,573 | ||
| Contract asset | 5,561 | 2,059 | ||
| Total Non-Current Assets | 188,623 | 32,751 | ||
| Total Assets | \$ 318,667 \$ |
210,665 | ||
| Liabilities | ||||
| Current Liabilities | ||||
| Current maturities of bank loans | \$ 2,631 \$ |
238 | ||
| Current maturities of lease liabilities | 1,154 | 1,072 | ||
| Current maturities of other long term liabilities | 17,986 | - | ||
| Trade payables | 25,104 | 16,110 | ||
| Other accounts payables | 7,142 | 7,547 | ||
| Deferred revenues | 40 | - | ||
| Total Current Liabilities | 54,057 | 24,967 | ||
| Non-Current Liabilities | ||||
| Bank loans | 17,407 | 36 | ||
| Lease liabilities | 3,160 | 3,593 | ||
| Contingent consideration | 21,995 | - | ||
| Other long-term liabilities | 43,929 | - | ||
| Deferred revenues | 15 | 2,025 | ||
| Employee benefit liabilities, net | 1,280 | 1,406 | ||
| Total Non-Current Liabilities | 87,786 | 7,060 | ||
| Shareholder's Equity | ||||
| Ordinary shares | 11,725 | 11,706 | ||
| Additional paid in capital net | 210,204 | 209,760 | ||
| Capital reserve due to translation to presentation currency | (3,490) | (3,490) | ||
| Capital reserve from hedges | 54 | 357 | ||
| Capital reserve from share-based payments | 4,643 | 4,558 | ||
| Capital reserve from employee benefits | (149) | (320) | ||
| Accumulated deficit | (46,163) | (43,933) | ||
| Total Shareholder's Equity | 176,824 | 178,638 | ||
| Total Liabilities and Shareholder's Equity | \$ 318,667 \$ |
210,665 |
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
| For the year ended December 31, |
Three months period ended December 31, |
|||||
|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||
| U.S. Dollars in thousands, other than per share information | ||||||
| Revenues from proprietary products | 75,521 | \$ 100,916 |
18,205 | \$ 23,283 |
||
| Revenues from distribution | 28,121 | 32,330 | 13,264 | 8,259 | ||
| Total revenues | 103,642 | 133,246 | 31,469 | 31,542 | ||
| Cost of revenues from proprietary products | 48,194 | 57,750 | 12,589 | 13,933 | ||
| Cost of revenues from distribution | 25,120 | 27,944 | 12,285 | 7,444 | ||
| Total cost of revenues | 73,314 | 85,694 | 24,874 | 21,377 | ||
| Gross profit | 30,328 | 47,552 | 6,595 | 10,165 | ||
| Research and development expenses | 11,357 | 13,609 | 3,448 | 3,274 | ||
| Selling and marketing expenses | 6,278 | 4,518 | 2,475 | 1,221 | ||
| General and administrative expenses | 12,636 | 10,139 | 3,833 | 3,006 | ||
| Other expenses and (incomes) | 753 | 49 | 141 | 15 | ||
| Operating income | (696) | 19,237 | (3,302) | 2,649 | ||
| Financial income | 295 | 1,027 | 18 | 162 | ||
| Income (expense) in respect of securities measured at fair value, net | - | 102 | - | - | ||
| Income (expense) in respect of currency exchange differences and derivatives instruments, net |
(207) | (1,535) | (281) | (839) | ||
| Financial expenses | (1,277) | (266) | (1,099) | (62) | ||
| Income before taxes | (1,885) | 18,565 | (4,664) | 1,910 | ||
| Taxes on income | 345 | 1,425 | 345 | 281 | ||
| Net (loss) Income | (2,230) | \$ 17,140 |
(5,009) | 1,629 | ||
| Other Comprehensive Income (loss) : | ||||||
| Amounts that will be or that have been reclassified to profit or loss when specific conditions are met: |
||||||
| Gain from securities measured at fair value through other comprehensive income |
- | (188) | - | |||
| Gain (loss) on cash flow hedges | - | 876 | (25) | 360 | ||
| Net amounts transferred to the statement of profit or loss for cash flow hedges | (303) | (528) | 44 | (255) | ||
| Items that will not be reclassified to profit or loss in subsequent periods: | ||||||
| Remeasurement gain (loss) from defined benefit plan | 171 | 64 | 171 | 64 | ||
| Tax effect | - | 19 | - | (10) | ||
| Total comprehensive (loss) income | (2,362) \$ |
\$ 17,383 |
(4,819) \$ |
\$ 1,788 |
||
| Earnings per share attributable to equity holders of the Company: | ||||||
| Basic (loss) income per share | (0.05) \$ |
\$ 0.39 |
(0.11) \$ |
\$ 0.04 |
||
| Diluted (loss) income per share | (0.05) \$ |
\$ 0.38 |
(0.11) \$ |
\$ 0.04 |
||
NON-IFRS MEASURES
EBITDA
| For the year ended December 31, |
Three months period ended December 31, |
|||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||||
| U.S. Dollars in thousands | ||||||||
| Net (loss) income | \$ (2,230) |
\$ | 17,140 | \$ | (5,009) | \$ | 1,629 | |
| Taxes on income | 345 | 1,425 | 345 | 281 | ||||
| Financial expense, net | 1,189 | 672 | 1,362 | 739 | ||||
| Depreciation and amortization expense | 5,609 | 4,897 | 1,997 | 1,265 | ||||
| Non-cash share-based compensation expenses | 529 | 977 | 25 | 124 | ||||
| EBITDA | \$ 5,442 |
\$ | 25,111 | \$ | (1,280) | \$ | 4,038 |
Adjusted EBITDA excluding referenced costs
| For the year ended December 31, |
Three months period ended December 31, |
|||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||||
| U.S. Dollars in thousands | ||||||||
| Adjusted EBITDA (as in table above) | \$ | 5,442 | \$ | 25,111 | \$ | (1,280) | \$ | 4,038 |
| Legal and other related costs associated with completing the acquisition transactions |
1,212 | - | 742 | - | ||||
| Excess severance remuneration | 560 | - | - | - | ||||
| Adjusted EBITDA excluding above referenced costs | \$ | 7,214 | \$ | 25,111 | \$ | (538) | \$ | 4,038 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the year ended December 31, |
December 31, | Three months period ended | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | ||||
| U.S. Dollars in thousands | |||||||
| Cash Flows from Operating Activities | |||||||
| Net (loss) Income | \$ | (2,230) | \$ | 17,140 | \$ (5,009) |
\$ | 1,629 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|||||||
| Adjustments to the profit or loss items: | |||||||
| Depreciation and impairment | 5,609 | 4,897 | 1,997 | 1,265 | |||
| Financial income, net | 1,189 | 672 | 1,362 | 739 | |||
| Cost of share-based payment | 529 | 977 | 25 | 124 | |||
| Taxes on income | 345 | 1,425 | 345 | 281 | |||
| Gain from sale of property and equipment | - | (7) | - | - | |||
| Change in employee benefit liabilities, net | 45 | 201 | (16) | 208 | |||
| Total adjustments | 7,717 | 8,165 | 3,713 | 2,617 | |||
| Changes in asset and liability items: | |||||||
| Decrease (increase) in trade receivables, net | (12,861) | 1,332 | (8,415) | 6,872 | |||
| Increase in other accounts receivables | (1,634) | 115 | (3,191) | (857) | |||
| Increase in inventories | (2,373) | 1,157 | 3,590 | 602 | |||
| Decrease (increase) in Contract asset and deferred expenses | (6,883) | (3,085) | (2,124) | (621) | |||
| Increase (decrease) in trade payables | 7,917 | (9,560) | 5,192 | 928 | |||
| Increase (decrease) in other accounts payables | (392) | 1,736 | 1,091 | 1,310 | |||
| Decrease in deferred revenues | 1,815 | 1,204 | 265 | 14 | |||
| Total changes in assets and liabilities | (14,411) | (7,101) | (3,592) | 8,248 | |||
| Cash received (paid) during the period for: | |||||||
| Interest paid | (228) | (209) | (89) | (51) | |||
| Interest received | 375 | 1,211 | 18 | 320 | |||
| Taxes paid | (42) | (101) | (10) | (14) | |||
| 105 | 901 | (81) | 255 | ||||
| Net cash (used in) provided by operating activities | \$ | (8,819) | \$ | 19,105 | \$ (4,969) |
\$ | 12,749 |
CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
| For the year ended December 31, |
Three months period ended December 31, |
|||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||||
| U.S. Dollars in thousands | ||||||||
| Cash Flows from Investing Activities | ||||||||
| Proceeds of investment in short term investments, net | \$ | 39,083 | \$ | (7,646) | - | \$ | 8,000 | |
| Purchase of property and equipment and intangible assets | (3,730) | (5,488) | (744) | (2,116) | ||||
| Business combination | (96,403) | - | (94,999) | |||||
| Proceeds from sale of property and equipment | - | 7 | - | - | ||||
| Net cash provided by (used in) investing activities | (61,050) | (13,127) | (95,743) | 5,884 | ||||
| Cash Flows from Financing Activities | ||||||||
| Proceeds from exercise of share base payments | 19 | 65 | 5 | 4 | ||||
| Receipt of long-term loan | 20,000 | - | 20,000 | - | ||||
| Repayment of lease liabilities | (1,221) | (1,103) | (318) | (288) | ||||
| Repayment of long-term loans | (205) | (492) | 16 | (119) | ||||
| Proceeds from issuance of ordinary shares, net | - | 24,894 | - | - | ||||
| Net cash used in financing activities | 18,593 | 23,364 | 19,703 | (403) | ||||
| Exchange differences on balances of cash and cash equivalent | (334) | (1,807) | (244) | (520) | ||||
| Increase in cash and cash equivalents | (51,610) | 27,535 | (81,253) | 17,710 | ||||
| Cash and cash equivalents at the beginning of the period | 70,197 | 42,662 | 99,840 | 52,487 | ||||
| Cash and cash equivalents at the end of the period | 18,857 | \$ | 70,197 | 18,587 | \$ | 70,197 | ||
| Significant non-cash transactions | ||||||||
| Purchase of property and equipment through leases | \$ | 845 | \$ | 539 | \$ 76 |
\$ | - | |
| Purchase of property and equipment | \$ | 1,001 | \$ | 722 | \$ 649 |
\$ | 722 |